Ocular tolerability and efficacy of intravitreal and subc sirolimus in patients with non-infectious uveitis: prima Study

Journal of Ophthalmic Inflammation and Infection

3, 32

DOI: 10.1186/1869-5760-3-32

Citation Report

#	Article	IF	Citations
1	Local therapies for inflammatory eye disease in translation: past, present and future. BMC Ophthalmology, 2013, 13, 39.	0.6	45
2	Emerging therapies for the treatment of uveitis: clinical trial observations. Clinical Investigation, 2013, 3, 951-966.	0.0	1
3	Rapamycin Inhibits the Production of Myofibroblasts and Reduces Corneal Scarring After Photorefractive Keratectomy. , 2013, 54, 7424.		45
4	Birdshot uveitis: current and emerging treatment options. Clinical Ophthalmology, 2013, 8, 73.	0.9	23
5	Temsirolimus Inhibits Proliferation and Migration in Retinal Pigment Epithelial and Endothelial Cells via mTOR Inhibition and Decreases VEGF and PDGF Expression. PLoS ONE, 2014, 9, e88203.	1.1	30
6	Pharmacotherapy for uveitis: current management and emerging therapy. Clinical Ophthalmology, 2014, 8, 1891.	0.9	53
7	Emerging Therapies for Noninfectious Uveitis: What May Be Coming to the Clinics. Journal of Ophthalmology, 2014, 2014, 1-7.	0.6	22
8	Review of the latest local treatments for uveitis. Expert Review of Ophthalmology, 2014, 9, 401-412.	0.3	1
9	Birdshot chorioretinopathy. Current Opinion in Ophthalmology, 2014, 25, 488-494.	1.3	18
10	Levels of sirolimus in saliva and blood following mouthwash application. Oral Diseases, 2014, 20, 768-772.	1.5	10
11	A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I. Expert Opinion on Pharmacotherapy, 2014, 15, 2141-2154.	0.9	24
12	Long-term Outcome of Intravitreal Triamcinolone Acetonide injection for the Treatment of Uveitis Attacks in BehÃ§et Disease. Ocular Immunology and Inflammation, 2014, 22, 27-33.	1.0	27
13	Review of Systemic Immunosuppression for Autoimmune Uveitis. Ophthalmology and Therapy, 2014, 3, 17-36.	1.0	21
14	New pharmacotherapy options for noninfectious posterior uveitis. Expert Opinion on Biological Therapy, 2014, 14, 1783-1799.	1.4	15
15	Comparison of posterior capsule opacification in rabbit eyes receiving different administrations of rapamycin. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 1111-1118.	1.0	10
16	Interobserver Agreement in Clinical Grading of Vitreous Haze Using Alternative Grading Scales. Ophthalmology, 2014, 121, 1643-1648.	2.5	31
17	Sirolimus for Retinal and Uveitic Diseases. Developments in Ophthalmology, 2016, 55, 276-281.	0.1	13
18	Local Therapeutic Options for Uveitic Cystoid Macular Edema. International Ophthalmology Clinics, 2015, 55, 39-61.	0.3	1

#	Article	IF	Citations
19	Clinical Trials in Noninfectious Uveitis. International Ophthalmology Clinics, 2015, 55, 79-110.	0.3	14
20	One-Year Outcomes of the SAVE Study:<u>S</u>irolimus as a Therapeutic<u>A</u>pproach for U<u>VE</u>itis. Translational Vision Science and Technology, 2015, 4, 4.	1.1	47
21	The Effect of Transient Local Anti-inflammatory Treatment on the Survival of Pig Retinal Progenitor Cell Allotransplants. Translational Vision Science and Technology, 2015, 4, 6.	1.1	9
22	In Vitro and In Vivo Sustained Zero-Order Delivery of Rapamycin (Sirolimus) From a Biodegradable Intraocular Device. , 2015, 56, 7331.		25
23	Intravitreal Sirolimus for the Treatment of Geographic Atrophy: Results of a Phase I/II Clinical Trial. Investigative Ophthalmology and Visual Science, 2015, 56, 330-338.	3.3	57
24	Subconjunctival Sirolimus in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial. American Journal of Ophthalmology, 2015, 159, 601-606.	1.7	18
25	Surface Engineering of Porous Silicon Microparticles for Intravitreal Sustained Delivery of Rapamycin. Investigative Ophthalmology and Visual Science, 2015, 56, 1070-1080.	3.3	29
26	Therapeutic options for the treatment of non-infectious uveitis. Expert Review of Ophthalmology, 2015, 10, 359-373.	0.3	2
27	Levels of sirolimus in saliva and blood following oral topical sustained-release varnish delivery system application. Cancer Chemotherapy and Pharmacology, 2015, 75, 969-974.	1.1	8
28	Assessment of changes in quality of life among patients in the SAVE Study - Sirolimus as therapeutic Approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis. Journal of Ophthalmic Inflammation and Infection, 2015, 5, 13.	1.2	21
29	The Suppression of Wound Healing Response with Sirolimus and Sunitinib Following Experimental Trabeculectomy in a Rabbit Model. Current Eye Research, 2015, 41, 1-10.	0.7	15
30	Nanomicellar Topical Aqueous Drop Formulation of Rapamycin for Back-of-the-Eye Delivery. AAPS PharmSciTech, 2015, 16, 610-622.	1.5	78
31	The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates. Ophthalmology, 2015, 122, 2311-2315.e1.	2.5	74
32	Autophagy in Ocular Pathophysiology. , 0, , .		1
34	Retinal Toxicity of Intravitreal Polyethylene Glycol 400. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 97-101.	0.6	12
35	Assessment of vitreous haze using ultra-wide field retinal imaging. Journal of Ophthalmic Inflammation and Infection, 2016, 6, 35.	1.2	13
36	Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA). Ophthalmology, 2016, 123, 2413-2423.	2.5	73
37	Uveitic macular edema. Eye, 2016, 30, 1277-1292.	1.1	89

#	Article	IF	Citations
38	Moving forward in uveitis therapy: preclinical to phase II clinical trial drug development. Expert Opinion on Investigational Drugs, 2016, 25, 195-214.	1.9	3
39	Non-Infectious Uveitis: Optimising the Therapeutic Response. Drugs, 2016, 76, 27-39.	4.9	21
40	Sirolimus for the treatment of noninfectious uveitis. Expert Opinion on Pharmacotherapy, 2016, 17, 127-135.	0.9	12
41	Immunosuppressive Treatment of Non-infectious Uveitis: History and Current Choices. Chinese Medical Sciences Journal, 2017, 32, 48-61.	0.2	12
42	Novel everolimus-loaded nanocarriers for topical treatment of murine experimental autoimmune uveoretinitis (EAU). Experimental Eye Research, 2018, 168, 49-56.	1.2	13
43	Treatment of Geographic Atrophy with Intravitreal Sirolimus. Ophthalmology Retina, 2018, 2, 441-450.	1.2	34
44	Novel therapies in the treatment of noninfectious uveitis. Expert Review of Ophthalmology, 2018, 13, 139-147.	0.3	1
45	Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis. Ophthalmology, 2018, 125, 1984-1993.	2.5	27
46	Safety and efficacy of tacrolimus-coated silicone plates as an alternative to mitomycin C in a rabbit model of conjunctival fibrosis. PLoS ONE, 2019, 14, e0219194.	1.1	1
47	In vivo and in vitro toxicity evaluation of liposome-encapsulated sirolimus. International Journal of Retina and Vitreous, 2019, 5, 35.	0.9	18
48	Emerging drugs for the treatment of noninfectious uveitis. Expert Opinion on Emerging Drugs, 2019, 24, 173-190.	1.0	11
49	Outcomes of treatment with sirolimus for non-infectious uveitis: a meta-analysis and systematic review . Clinical Ophthalmology, 2019, Volume 13, 649-669.	0.9	11
50	New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. Seminars in Arthritis and Rheumatism, 2019, 49, 438-445.	1.6	78
51	Update in treatment of uveitic macular edema . Drug Design, Development and Therapy, 2019, Volume 13, 667-680.	2.0	40
52	New therapies in development for the management of nonâ€infectious uveitis: A review. Clinical and Experimental Ophthalmology, 2019, 47, 396-417.	1.3	38
53	Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbitsâ€™ eyes. Documenta Ophthalmologica, 2019, 138, 3-19.	1.0	10
54	Effect of Rapamycin Microspheres in SjÃ¶gren Syndrome Dry Eye: Preparation and Outcomes. Ocular Immunology and Inflammation, 2019, 27, 1357-1364.	1.0	11
55	Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment. Ophthalmology, 2020, 127, 1405-1415.	2.5	23

#	Article	IF	Citations
56	PYK-1105: Preclinical Evaluation of a Novel Biodegradable Vitreous Substitute for Retinal Tamponade. Journal of Vitreoretinal Diseases, 2021, 5, 32-39.	0.2	6
57	A Review of Local Therapy for the Management of Cystoid Macular Edema in Uveitis. Asia-Pacific Journal of Ophthalmology, 2021, 10, 87-92.	1.3	7
58	Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update. Expert Review of Clinical Pharmacology, 2021, 14, 179-210.	1.3	8
59	A grafted copolymer-based nanomicelles for topical ocular delivery of everolimus: Formulation, characterization, ex-vivo permeation, in-vitro ocular toxicity, and stability study. European Journal of Pharmaceutical Sciences, 2021, 159, 105735.	1.9	44
60	Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective. Survey of Ophthalmology, 2022, 67, 388-410.	1.7	8
61	Toxicity Evaluation of a Novel Rapamycin Liposomal Formulation After Subconjunctival and Intravitreal Injection. Journal of Ocular Pharmacology and Therapeutics, 2021, 37, 261-276.	0.6	5
62	Intravitreal lupeol: A new potential therapeutic strategy for noninfectious uveitis. Biomedicine and Pharmacotherapy, 2021, 143, 112145.	2.5	3
63	Emerging therapies in the management of macular edema: a review. F1000Research, 2019, 8, 1413.	0.8	35
64	The Neuroprotective Effect of Rapamycin as a Modulator of the mTOR-NF-Î¹B Axis during Retinal Inflammation. PLoS ONE, 2016, 11, e0146517.	1.1	43
65	Therapies in Development for Non-Infectious Uveitis. Current Molecular Medicine, 2015, 15, 565-577.	0.6	13
66	A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. Health Technology Assessment, 2017, 21, 1-170.	1.3	26
67	Intravitreal therapeutic agents in noninfectious uveitic macular edema. Indian Journal of Ophthalmology, 2018, 66, 1060.	0.5	13
68	Intravitreal drug administration for treatment of noninfectious uveitis. World Journal of Ophthalmology, 2015, 5, 125.	0.1	0
69	Immunosuppressives and biologicals in uveitis: The way forward â€“ Current concepts. TNOA Journal of Ophthalmic Science and Research, 2019, 57, 139.	0.0	1
70	T Cell Inhibitors. , 2019, , 45-56.		0
71	Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye. Medical Hypothesis, Discovery, and Innovation in Ophthalmology, 2013, 2, 113-20.	0.4	13
72	Understanding autoimmunity in the eye: from animal models to novel therapies. Discovery Medicine, 2014, 17, 155-62.	0.5	21
73	The Effect of Different Dosing Schedules of Intravitreal Sirolimus, a Mammalian Target of Rapamycin (mTOR) Inhibitor, in the Treatment of Non-Infectious Uveitis (An American Ophthalmological Society) Tj ETQq1 1 0.784314 rgBT /Ove	1.4	8

#	Article	IF	Citations
74	Current Knowledge of Biologics in Treatment of Noninfectious Uveitis. Journal of Ocular Pharmacology and Therapeutics, 2022, 38, 203-222.	0.6	6
75	Therapeutic Effect of Rapamycin-Loaded Small Extracellular Vesicles Derived from Mesenchymal Stem Cells on Experimental Autoimmune Uveitis. Frontiers in Immunology, 2022, 13, 864956.	2.2	14
76	Utilisation of composite endpoint outcome to assess efficacy of tocilizumab for non-infectious uveitis in the STOP-Uveitis Study. British Journal of Ophthalmology, 2023, 107, 1197-1201.	2.1	3
77	A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology. Therapeutic Advances in Ophthalmology, 2022, 14, 251584142210974.	0.8	5
78	Pharmacokinetics of Sirolimus in a Novel Liposome Delivery System in Selected Ocular Tissues and Plasma Following a Single Subconjunctival Injection in Dutch Belted Rabbits. Journal of Ocular Pharmacology and Therapeutics, 0, , .	0.6	1
79	A review of patient-reported outcome measures used in uveitis. Survey of Ophthalmology, 2023, 68, 225-240.	1.7	3
80	Sirolimus loaded chitosan functionalized PLGA nanoparticles protect against sodium iodate-induced retinal degeneration. Journal of Drug Delivery Science and Technology, 2023, 82, 104369.	1.4	4